TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of Type 2 Diabetes~* Stable dose of metformin for more than 8 weeks~Exclusion Criteria:~* Subjects with Addison's disease or Cushing's Syndrome~* Type 1 diabetes mellitus or secondary forms of diabetes~* Subjects with uncontrolled thyroid disease~* History of renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A - INCB013739 & Metformin (Type: EXPERIMENTAL): INCB013739 5 mg QD and Metformin
- Treatment B - INCB013739 & Metformin (Type: EXPERIMENTAL): INCB013739 15 mg QD and Metformin
- Treatment C - INCB013739 & Metformin (Type: EXPERIMENTAL): INCB013739 50 mg QD and Metformin
- Treatment D - INCB013739 & Metformin (Type: EXPERIMENTAL): INCB013739 100 mg QD and Metformin
- Treatment E - INCB013739 & Metformin (Type: EXPERIMENTAL): INCB013739 200 mg QD and Metformin
- Treatment F - Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HCV RNA is positive~* Genotype 6~* Treatment naive~* Raised ALT~Exclusion Criteria:~* Active substance abuse~* Poorly controlled psychiatric disease~* HBsAg positive~* Anti-HIV positive~* Suffering from other significant concurrent medical conditions including chronic liver diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 24-Week treatment group (Type: EXPERIMENTAL): Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
- 48-Week treatment group (Type: ACTIVE_COMPARATOR): Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exercise Intolerance in Elderly Patients With Diastolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Heart failure clinical score greater than or equal to 3~* Age 60 and over~* Normal ejection fraction greater than or equal to 50%~* BMI greater than or equal to 30~Exclusion Criteria:~* Valvular heart disease~* Significant change in cardiac medication \<4 weeks~* Uncontrolled hypertension~* Recent or debilitating stroke~* Cancer or other noncardiovascular conditions with life expectancy less than 2 years~* Significant Anemia~* Renal insufficiency (creatinine \>2.5mg/dl)~* Psychiatric disease- uncontrolled major psychoses, depressions, dementia, or personality disorder~* Plans to leave area within 6 months~* Refuses informed consent~* Failure to pass screening test:pulmonary function, echocardiogram,or exercise

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exercise Training (Type: ACTIVE_COMPARATOR): Exercise participants will undergo a 1-hour supervised exercise program 3 times per week for 20 weeks consisting primarily of walking exercise using an individualized exercise prescription based on the initial exercise stress testing results.
- Dietary Intervention (Type: ACTIVE_COMPARATOR): A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb) weight loss per week.
- Attention control (Type: ACTIVE_COMPARATOR): Attention control participants will be provided a counseling session regarding general health education at baseline and will be contacted by staff via telephone every 2 weeks to discuss general health status.
- Diet and Exercise (Type: ACTIVE_COMPARATOR): A hypocaloric diet will be developed to achieve a 2450 kcal/week deficit in addition to undergoing a 1-hour supervised exercise program 3 times per week for 20 weeks consisting primarily of walking exercise using an individualized exercise prescription based on the initial exercise stress testing results.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NVA237 BID Versus Placebo Twelve-week Efficacy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria: 1. Patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with airflow obstruction of level 2 and 3 according to the current Global initiative for chronic Obstructive Lung Disease (GOLD) strategy (2011). 2. Patients with Forced Expiratory Volume in one second (FEV1) ≥ 30% and \<80 % of the predicted normal, and FEV1/FVC \< 0.70 when measured 45 min after the inhalation of 84 µg ipratropium bromide.~3. Current or ex-smokers with at least 10 cigarette pack years smoking history.~Exclusion criteria:~1. Patients with a history of long QT syndrome, with a prolonged QTc measured during screening, or patients who have a clinically significant ECG abnormality at screening.~2. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.~3. Pregnant or nursing (lactating) women. Women of childbearing potential unless using an effective method of contraception.~4. Patients who in the judgment of the investigator, would be at potential risk if enrolled into the study.~5. Patients who have a clinically significant concomitant disease at screening, including but not limited to clinically significant laboratory abnormalities, clinically significant renal, cardiovascular, neurological, endocrine, immunological, psychiatric, gastrointestinal, hepatic, or hematological abnormalities, or with uncontrolled diabetes, which could interfere with the assessment of the efficacy and safety of the study treatment.~6. Patients with a body mass index (BMI) of more than 40 kg/m2.~7. Patients contraindicated for treatment with, or having a history of reactions/ hypersensitivity to anticholinergic agents, long and short acting beta-2 agonists, or sympathomimetic amines.~8. Patients with any history of asthma, with onset of symptoms prior to age 40 years, or patients with a high blood eosinophil count during screening.~Other protocol-defnied inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NVA237 (Type: EXPERIMENTAL): NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Modulation of Cognitive Control Signals in Prefrontal Cortex by Rhythmic Transcranial Magnetic Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* Between the ages of 18 and 35~* Right handed~* Able to provide informed consent~* Willing to comply with all study procedures~* Available for the duration of the study~* Speak and understand English.~Exclusion Criteria:~* Attention Deficit Hyperactivity Disorder (currently under treatment)~* Neurological disorders and conditions, including, but not limited to: History of epilepsy Seizures (except childhood febrile seizures) -Dementia~* History of stroke~* Parkinson's disease~* Multiple sclerosis~* Cerebral aneurysm~* Brain tumors~* Medical or neurological illness or treatment for a medical disorder that could interfere with study participation (e.g., unstable cardiac disease, HIV/AIDS, malignancy, liver or renal impairment)~* Prior brain surgery -Any brain devices/implants, including cochlear implants and aneurysm clips -Cardiac pacemaker -Any other implanted electronic device -History of current traumatic brain injury -(For females) Pregnancy or breast feeding -Anything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- TMS to frontal cortex followed by TMS to parietal cortex (Type: EXPERIMENTAL): Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the frontal cortex on the scalp. In their second session, the TMS coil will be placed over the parietal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.
- TMS to parietal cortex followed by TMS to frontal cortex (Type: EXPERIMENTAL): Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the parietal cortex on the scalp. In their second session, the TMS coil will be placed over the frontal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Remifentanil and Flurbiprofen in Sedation and Analgesia for ESWL of Pancreatic Stone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 18-65 years~* ASA I-II~* ESWL indication was met~Exclusion Criteria:~* patients with hypertension~* patients compromised in cardiopulmonary function~* patients undergoing ESWL for the second or more times

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rem group (Type: ACTIVE_COMPARATOR): Patients in this group receive single infusion of remifentanil with target concentration infusion.
- Flur group (Type: EXPERIMENTAL): Patients in this group receive both infusion of flurbiprofen and remifentanil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~-Cirrhotic patients with acute variceal bleeding, without minimal or clinical hepatic encephalopathy according to PHES, CFF and West-Haven criteria~Exclusion Criteria:~* Age under 18 year-old or over 65 year-old, with any other neuropsychiatric disorder or dementia, presence of active bacterial or fungal infections, receiving antibiotics for any cause, previous diagnosis of hepatic encephalopathy and receiving therapy with lactulose, rifaximin, L-ornithine L-aspartate, source of bleeding different from variceal origin, serum creatinine greater than 2.0 mg/dl or with chronic renal failure. Therapy in the previous six months with any of the drugs that will be used in this clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- lactulose (Type: EXPERIMENTAL): None
- L-ornithine L-aspartate (Type: EXPERIMENTAL): None
- Rifaximin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase1 Syudy to Evaluate the Safety and PK/PD of Human Antithrombin III

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ages 19 to 40~* Body weight: More than 50kg~* Healthy male subject~Exclusion Criteria:~* Hb\<14g/dL, Hct\<42%~* ATIII hypersensitivity

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Antithrombin III (Type: ACTIVE_COMPARATOR): None
- SK Antithrombin III (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of Idiopathic Thrombocytopenic Purpura (ITP) according to standard criteria.~* Platelet count ≤ 20 x 10\^9/L.~Key Exclusion Criteria:~* Chronic refractory ITP patients.~* Thrombocytopenia secondary to other diseases, or drug related thrombocytopenia.~* Administration of IGIV, anti-D, or other platelet enhancing drugs within 30 days before enrollment.~* Administration of thrombocyte concentrates within 72 hours before baseline.~* Experimental treatment (eg, rituximab) within 3 months before enrollment.~* Prophylactic preoperative treatment for elective splenectomy.~* Severe liver or kidney disease.~* Pregnant or nursing female.~* History of hypersensitivity to blood or plasma derived products.~* Emergency operation.~* Live viral vaccination within the last month prior to study entry.~* Known IgA deficiency and antibodies against IgA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Octagam 10% 1 g/kg/day (Type: EXPERIMENTAL): Participants received Octagam 10% (human normal immunoglobulin) 1 g/kg intravenously once a day for 2 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Management of Allergic Rhinitis Patients With Nasal Steroids and NeilMed® Sinus Rinse™ System With Isotonic Saline

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* male or female adults (aged 18-99) diagnosed with rhinitis who have completed one month of pharmacotherapy exclusively with nasal steroids and allergy testing.~Exclusion Criteria:~* male and female adults who have been diagnosed with sinusitis, cystic fibrosis, or immune deficiency or those unable or unwilling to perform saline irrigations for two months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- NeilMed® Sinus Rinse™ System (Type: OTHER): NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who completed the 13-week treatment of painful diabetic peripheral neuropathy in Study A0081163.~* Patients must be able to understand and cooperate with study procedures and have signed a written informed consent prior to entering the study~Exclusion Criteria:~* Patients who experienced serious adverse events in the preceding study (A0081163) that were determined by the investigator or the study sponsor to be causally related to the study medication.~* Patients exhibiting treatment non-compliance in the preceding study (A0081163)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- pregabalin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-guided Intermediate Cervical Plexus Block

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* internal carotid stenosis: open surgical revascularization~* age over 18 years~* written informed consent~Exclusion Criteria:~* allergy (local anesthetics)~* pregnancy~* participation in other studies~* drug addiction~* non-cooperative patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- with perivascular block (Type: EXPERIMENTAL): 1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%) 3. perivascular block (5ml prilocaine 1%)
- without perivascular block (Type: EXPERIMENTAL): 1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioavailability and Bioequivalence of Ezetimibe Tablets in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female subjects ≥18 years of age~* The body mass index is in the range of 18.0-26.0 kg/m2 (including the critical value).~* The weight of male is not less than 50.0 kg, and that of female is not less than 45.0 kg.~* Serum total cholesterol was between 2.9 and 5.0mmol/L (not including critical value).~Exclusion Criteria:~* any medical history of cardiovascular, digestive, respiratory, nervous or ematological diseases~* hepatic/renal impairment~* abnormal vital signs~* drug or alcohol abuse~* smoking ≥5 cigarettes per day ,~* donation(≥300ml) o~* enrollment in other clinical trials during the 3 months prior to screening~* allergic to ezetimibe or its excipients~* any use of other prescription drugs or vitamins or caffeine/xanthine-rich beverages 48h prior to taking medication~* lactating or pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ezetimibe tablet (Type: EXPERIMENTAL): ezetimibe tablet test formulation at a single dose of 10 mg
- ezetimibe tablet(Ezetrol ®) (Type: ACTIVE_COMPARATOR): ezetimibe tablet reference formulation at a single dose of 10 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male volunteers, aged 18 to 45 years old.~* No active or chronic disease following a detailed medical and surgical history and complete physical examination.~* A BMI between 18 to 30 kg/m2 inclusive.~* Use of a highly effective form of birth control for the duration of the study and until 90 days after the last dose.~Exclusion Criteria:~* Any clinically relevant current or history of conditions or illnesses.~* Clinically significant symptoms of infection within 5 days of the first dosing day or a history of recurrent infections.~* Any suspicion or history of alcohol abuse and/or consumption of other drugs of abuse.~* Smokers unable or unwilling to restrict to 5 cigarettes daily during the study and to not smoke during the stay at the clinic.~* Any cardiac abnormalities.~* Blood donation over 450 mL within three months prior to screening.~* Participation in an investigational drug or device study within 3 months prior to dosing.~* Corticosteroid use within 3 months prior to dosing.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Part 1: Placebo (PL) (Type: PLACEBO_COMPARATOR): None
- Part 1: Single Ascending Doses (SAD) of RO6836191 (Type: EXPERIMENTAL): None
- Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet (Type: PLACEBO_COMPARATOR): None
- Part 2: PL: NS followed by LS diet (Type: PLACEBO_COMPARATOR): None
- Part 2: RO6836191: LS followed by NS diet (Type: EXPERIMENTAL): None
- Part 2: RO6836191: NS followed by LS diet (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete